Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction

Drugs in R and D

Volumn 3, Issue 4, 2002, Pages 239-249

  Gurevich, Andrey K ^a   Falk, Sandor A ^a   Nemenoff, Raphael A ^a   Weinberger, Howard D ^a   Summer, Sandra N ^a   Rizeq, Mona ^b   Gengaro, Patricia E ^a   Bedigian, Martin P ^c   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DNA; MESSENGER RNA; MUSCLE PROTEIN; OLIGONUCLEOTIDE; VALSARTAN;

ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIASTOLE; DNA MICROARRAY; DRUG MECHANISM; ECHOCARDIOGRAPHY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC CODE; HEART DILATATION; HEART DISEASE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; IMMUNE RESPONSE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; UNINDEXED SEQUENCE;

EID: 0037965140     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203040-00004     Document Type: Article

References (45)

1. Ghali JK, Cooper R, Ford E. Trends in hospitalization for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990; 150: 769-73
2. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988; 319: 1065-72
3. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319: 1127-34
4. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990; 113: 155-9
5. Schrier RW. A unifying hypothesis of body fluid volume regulation: the Lilly Lecture 1992. J R Coll Physicians Lond 1992; 26: 295-306
6. Schrier RW, Niederberger M. Paradoxes of body fluid volume regulation in health and disease: a unifying hypothesis. West J Med 1994; 161: 393-408
7. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85
8. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol 2001; 21: 157-72
9. Cadnapaphornchai MA, Gurevich AK, Weinberger HD, et al. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96: 122-31
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35
11. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53
13. The US Carvedilol Heart Failure Study Group. The effect of carvedilol on mortality and morbidity in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55
14. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16
15. Colucci WC, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-6
16. Genth-Zotz S, Zotz RJ, Sigmund M, et al. MIC trial. Metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail 2000; 2: 175-81
17. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-302
18. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
19. Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis: results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol 1996; 28: 20-4
20. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000; 36: 276-81
21. Beller KD, Diedrich F, Sponer G. The effect of carvedilol on contrast echocardiography in comparison to metoprolol in conscious dogs. Arzneimittel Forschung 1999; 49: 830-4
22. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999; 33: 1926-34
23. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645-51
24. Schwinger RH. The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients: the results of the RALES study. The Randomized Aldactone Evaluation Study. Dtsch Med Wochenschr 1999; 124: 987-8
25. Kulbertus H. Study of the month. The RALES study (randomized aldactone evaluation study). Rev Med Liege 1999: 54: 770-2
26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17
27. Jin H, Yang R, Awad TA, et al. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation 2001; 103: 736-42
28. Schrier RW, Abdallah JG, Weinberger HH, et al. Therapy of heart failure. Kidney Int 2000; 57: 1418-25
29. Ecder T, Korular D, Gurevich AK, et al. Therapy of heart failure. Curr Opin Invest Drugs 2001; 2: 81-6
30. Parmley WW. Pathophysiology of congestive heart failure. Am J Cardiol 1985; 56: 7A-11A
31. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51
32. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res 1981; 49: 618-26
33. Agabiti-Rosei E, Muiesan ML. Prognostic significance of left ventricular hypertrophy regression. Adv Exp Med Biol 1997; 432: 199-205
34. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13
35. Ojamaa K, Kenessey A, Shenoy R, et al. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab 2000; 279: E1319-24
36. Dixon IMC, Ju H, Jassal DS, et al. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 1996; 165: 31-45
37. Rockman HA, Wachhorst SP, Mao L, et al. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994; 266: H2468-75
38. Kim S, Ohta K, Hamaguchi A, et al. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 1996; 118: 549-56
39. Li H, Simon H, Bocan TMA, et al. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000; 46: 298-306
40. Makoto K, Kensuke E, Takashi M, et al. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol 2000; 35: 932-6
41. Sandmann S, Yu M, Unger T. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT1 and AT2 receptor antagonists and ACE inhibitor. Br J Pharmacol 2001; 132: 767-77
42. Friddle CJ, Koga T, Rubin EM, et al. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci U S A 2000; 97: 6745-50
43. Sehl PD, Tai JT, Hillan KJ, et al. Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury. Circulation 2000; 101: 1990-9
44. Gidh-Jain M, Huang B, Jain P, et al. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J Mol Cell Cardiol 1998; 30: 627-37
45. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992; 44: 479-602